Coeptis Therapeutics Holdings Inc
COEP14.640USD
-0.110-0.75%
Cierre 11/05, 16:00（ET）Cotizaciones retrasadas 15 min
61.00MCap. mercado
PérdidaP/E TTM
Más Datos de Coeptis Therapeutics Holdings Inc Compañía
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and advanced robotic process automation capabilities. Its Coeptis Technologies division is focused on diversifying and enhancing its growth potential. Its subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
Información de Coeptis Therapeutics Holdings Inc
Símbolo de cotizaciónCOEP
Nombre de la empresaCoeptis Therapeutics Holdings Inc
Fecha de salida a bolsaDec 17, 2020
Director ejecutivo- -
Número de empleados5
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 17
Dirección105 Bradford Road, Suite 420
CiudadWEXFORD
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal15090
Teléfono17249346467
Sitio Webhttps://coeptistx.com/
Símbolo de cotizaciónCOEP
Fecha de salida a bolsaDec 17, 2020
Director ejecutivo- -
Ejecutivos de Coeptis Therapeutics Holdings Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. David Mehalick
Mr. David Mehalick
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
130.07K
--
Ms. Christine Sheehy
Ms. Christine Sheehy
Vice President - Compliance, Secretary
Vice President - Compliance, Secretary
50.53K
--
Mr. Daniel (Dan) Yerace
Mr. Daniel (Dan) Yerace
Vice President - Operations, Director
Vice President - Operations, Director
45.53K
--
Mr. Christopher Calise
Mr. Christopher Calise
Independent Director
Independent Director
--
--
Mr. Christopher Cochran
Mr. Christopher Cochran
Independent Director
Independent Director
--
--
Mr. Philippe Deschamps
Mr. Philippe Deschamps
Independent Director
Independent Director
--
--
Dr. Tara Maria Desilva, Ph.D.
Dr. Tara Maria Desilva, Ph.D.
Independent Director
Independent Director
--
--
Mr. Brian Cogley
Mr. Brian Cogley
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. David Mehalick
Mr. David Mehalick
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
130.07K
--
Ms. Christine Sheehy
Ms. Christine Sheehy
Vice President - Compliance, Secretary
Vice President - Compliance, Secretary
50.53K
--
Mr. Daniel (Dan) Yerace
Mr. Daniel (Dan) Yerace
Vice President - Operations, Director
Vice President - Operations, Director
45.53K
--
Mr. Christopher Calise
Mr. Christopher Calise
Independent Director
Independent Director
--
--
Mr. Christopher Cochran
Mr. Christopher Cochran
Independent Director
Independent Director
--
--
Mr. Philippe Deschamps
Mr. Philippe Deschamps
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: dom., 2 de nov
Actualizado: dom., 2 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Calise (Chris)
6.49%
Mehalick (David)
2.70%
Armistice Capital LLC
1.97%
Sheehy (Christine Elise)
1.05%
Yerace (Daniel Alexander)
0.94%
Otro
86.86%
Accionistas
Accionistas
Proporción
Calise (Chris)
6.49%
Mehalick (David)
2.70%
Armistice Capital LLC
1.97%
Sheehy (Christine Elise)
1.05%
Yerace (Daniel Alexander)
0.94%
Otro
86.86%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
11.27%
Corporation
2.13%
Hedge Fund
1.97%
Investment Advisor
0.64%
Investment Advisor/Hedge Fund
0.42%
Otro
83.58%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
31
146.21K
3.03%
+12.13K
2025Q2
42
850.21K
24.20%
+80.97K
2025Q1
44
802.79K
23.54%
+88.77K
2024Q4
46
470.87K
21.82%
-146.34K
2024Q3
60
665.36K
32.36%
-151.44K
2024Q2
63
660.64K
38.75%
-415.23K
2024Q1
86
813.98K
47.41%
-385.62K
2023Q4
86
964.24K
63.23%
-125.48K
2023Q3
87
697.73K
55.24%
-487.79K
2023Q2
87
705.35K
60.53%
-350.78K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Calise (Chris)
312.69K
6.49%
--
--
Sep 11, 2025
Mehalick (David)
130.07K
2.7%
--
--
Sep 11, 2025
Armistice Capital LLC
94.77K
1.97%
+94.77K
--
Sep 30, 2024
Sheehy (Christine Elise)
50.53K
1.05%
--
--
Sep 11, 2025
Yerace (Daniel Alexander)
45.53K
0.94%
-5.00K
-9.89%
Sep 11, 2025
The Vanguard Group, Inc.
27.53K
0.57%
+3.09K
+12.65%
Jun 30, 2025
Geode Capital Management, L.L.C.
20.28K
0.42%
+311.00
+1.56%
Jun 30, 2025
Salkind (Gene)
4.21K
0.09%
--
--
Sep 11, 2025
Sea Otter Advisors LLC
2.25K
0.05%
--
--
Jun 30, 2024
Steward Partners Investment Advisory, LLC
1.00K
0.02%
--
--
Jun 30, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Fecha
Tipo
Relación
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
